Latest Regulatory News

Paradigm Biopharmaceuticals has entered a binding agreement with AVet Health to co-develop and license a novel oral therapy for veterinary osteoarthritis in Australia and New Zealand, unlocking new market potential while advancing its human clinical trials.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

DeSoto Resources has significantly expanded its footprint in Guinea’s prolific Siguiri Basin by acquiring three new reconnaissance projects and advancing multiple exploration programs across its portfolio.

Memphasys Limited has secured Therapeutic Goods Administration approval for its Felix™ System two months ahead of schedule, enabling immediate commercial sales and clinical use in Australia.

DGR Global has been flagged by ASX for breaching Listing Rule 10.1 after advancing $500,000 without prior shareholder approval. The company is now preparing to seek retroactive approval and address further funding tranches.

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, reflecting robust project engagement and disciplined cost management. The company also plans increased investment in internal technology.

Lunnon Metals has officially begun mining at its Lady Herial project, marking the first new mine on the Foster belt in over 30 years and targeting significant gold production amid record prices.

Altamin Limited has obtained a retrospective Environmental Impact Assessment approval for its Gorno Project in Italy, strengthening its regulatory footing and supporting strategic options for development.

Olympio Metals has confirmed promising high-grade gold soil anomalies at its Bousquet Gold Project in Quebec, highlighting a new priority target and preparing to resume drilling following significant historical intercepts.

News Corporation reported a 4% revenue increase to US$4.506 billion for the half-year ended December 2025, while net income declined 9% to US$305 million. The company declared an interim dividend and continued its stock repurchase program amid mixed segment performances and ongoing legal challenges.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

Credit stocks swung hard, with Credit Corp sliding despite steady profits and a busy acquisition agenda. Payments and capital management stories did the heavy lifting elsewhere, from Klevo’s Mastercard milestones to Regal’s buy-back.